IPG Investment Advisors LLC Acquires Shares of 8,712 DaVita Inc. $DVA

IPG Investment Advisors LLC acquired a new stake in DaVita Inc. (NYSE:DVA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,712 shares of the company's stock, valued at approximately $1,938,000.

Several other institutional investors have also recently made changes to their positions in DVA. Berkshire Hathaway Inc purchased a new stake in DaVita in the second quarter valued at $6,425,269,000. California State Teachers Retirement System raised its stake in shares of DaVita by 18,932.5% during the 2nd quarter. California State Teachers Retirement System now owns 8,610,866 shares of the company's stock valued at $1,915,745,000 after buying an additional 8,565,623 shares during the last quarter. BlackRock Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at about $547,520,000. Invesco Ltd. lifted its holdings in shares of DaVita by 2.0% in the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company's stock valued at $223,122,000 after buying an additional 32,358 shares during the period. Finally, Morgan Stanley boosted its stake in shares of DaVita by 5.1% in the fourth quarter. Morgan Stanley now owns 1,477,045 shares of the company's stock worth $167,807,000 after buying an additional 71,156 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Waters sold 15,405 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.90% of the company's stock.

DaVita Trading Up 1.7%

NYSE:DVA opened at $183.11 on Thursday. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49. The stock has a 50 day moving average of $206.15 and a two-hundred day moving average of $185.25. The firm has a market cap of $11.68 billion, a P/E ratio of 14.98, a price-to-earnings-growth ratio of 0.47 and a beta of 0.83.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The business's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Zacks Research cut DaVita from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. Weiss Ratings upgraded DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 5th. Barclays raised their price objective on DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a report on Wednesday, August 5th. Finally, TD Cowen upgraded DaVita from a "hold" rating to a "buy" rating and increased their target price for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, DaVita presently has an average rating of "Moderate Buy" and an average price target of $233.43.

DaVita Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.